NIH Director Outlines New Research Priorities and Launches Grant Review

The National Institutes of Health (NIH) has unveiled a new set of research priorities under
the leadership of Director Jayanta “Jay” Bhattacharya. The updated vision highlights twelve
focus areas, including autism, chronic disease, health disparities, and the use of artificial
intelligence in research. While these initiatives are designed to guide the agency toward a
more unified strategy, the announcement also introduced a new internal review process
for NIH’s grant funding portfolio a move raising both anticipation and concern among
researchers and staff.

In an effort to create a unified research strategy, Director Bhattacharya emphasized that
the outlined priorities are intended to align NIH’s 27 institutes and centers, while rebuilding
public trust in biomedical research. The plan includes commitments to advance scientific
training based strictly on merit, improve reproducibility of results through replication
studies, and expand opportunities to publish negative findings. Nutrition research,
particularly regarding childhood obesity, and the development of a national data platform
integrating Medicare and Medicaid records are also among the key priorities.

Other initiatives include strengthening autism data science, creating alternatives to animal
testing, and encouraging international collaboration with additional oversight. HIV
research will shift toward implementation science, ensuring treatments reach at-risk
communities more effectively.

One area drawing particular attention is health disparities research. Bhattacharya stressed
that studies must focus on measurable factors such as redlining and housing
discrimination, rather than broader systemic claims. Importantly, NIH is urging
researchers to move beyond documenting disparities to developing practical, solution-
oriented approaches.

Alongside the priority list, Bhattacharya called for a comprehensive review of existing and
future NIH-funded projects. Effective immediately, all funding announcements,
applications, and active grants will be reassessed to ensure alignment with the new
strategic goals. Projects found out of step may be paused, restricted, or discontinued.

This sweeping review has prompted unease across the research community. Some NIH
staff expressed frustration at the lack of clear timelines, fearing the process could delay
grant disbursements. Former NIH institute director Jeremy Berg noted that the absence of
community input is troubling, warning that the review risks slowing down progress and
creating inconsistencies in how grants are handled.

Bhattacharya framed these steps as necessary for delivering results that matter most to
the public, reinforcing NIH’s mission to advance biomedical knowledge. However, with
new oversight measures and tightened alignment requirements, the coming months will
test whether these reforms can accelerate innovation without hindering critical research
already underway. Hopefully pharmas will find ways to provide viable treatments for
everyone.

NIH Director Outlines New Research Priorities and Launches Grant Review

Myra Fonville

Myra Fonville is the Executive Editor of Interim Visits magazine.  Myra is a former pharmacist who has worked in the clinical research industry for the past 28 years.  She brings a wealth of knowledge about pharmacy, pharmaceuticals and clinical research.  Myra is very passionate about diversity and health equity which is one of the primary reasons Interim Visits is educating the public about the importance of clinical trials.